Early eczema drug trial halted after limited testing

NCT ID NCT05984784

Terminated Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study aimed to test the safety and effectiveness of an experimental drug called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis). Participants received the drug or a placebo through IV infusions over several weeks. The trial was terminated early, and only a small number of people were enrolled before it stopped.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Amicis Research Center

Northridge, California, 91324, United States
Amicis Research Center

Valencia, California, 91355, United States
Brunswick Dermatology Center

Fredericton, New Brunswick, E3B 1G9, Canada
Central Sooner Research

Oklahoma City, Oklahoma, 73170, United States
Centre de Recherche Saint-Louis (Québec)

Québec, G1W4R4, Canada
DermEffects

London, Ontario, N6H 5L5, Canada
Markowitz Medical, LLC

New York, New York, 10128, United States
Medical Research Center of Miami II Inc

Miami, Florida, 33134, United States
Optimal Research Sites

Orange City, Florida, 32763, United States
Paddington Testing Co, Inc

Philadelphia, Pennsylvania, 19103, United States
Revival Research Institute, LLC

Troy, Michigan, 48084, United States
USF Carol and Frank Morsani Center for Advanced Healthcare

Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.

AD ATOPIC DERMATITIS MODERATE TO SEVERE ATOPIC DERMATITIS